<DOC>
	<DOCNO>NCT00002306</DOCNO>
	<brief_summary>To evaluate safety effectiveness fluconazole treatment acute cryptococcal meningitis patient unsatisfactory response experience unacceptable toxicity amphotericin B .</brief_summary>
	<brief_title>A Study Fluconazole Treatment Cryptococcal Meningitis Patients Who Have Not Had Success With Amphotericin B</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Immunosuppressant therapy . Antiviral therapy zidovudine . Prophylaxis Pneumocystis carinii pneumonia . Aerosolized pentamidine . Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Not previously treat acute cryptococcal meningitis eligible Pfizer Central Research , protocol # 159 . Patients must baseline cerebrospinal fluid ( CSF ) culturepositive Cryptococcus neoformans . Written informed consent must obtain patient , either patient patient 's legal guardian . Each individual patient must approve Pfizer Central Research prior study entry . Prior Medication : Allowed : Immunosuppressant therapy . Antiviral therapy zidovudine . Prophylaxis Pneumocystis carinii pneumonia . Aerosolized pentamidine . Exclusion Criteria Coexisting Condition : Patients follow exclude : Evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole azoles . Moderate severe liver disease . Concurrent Treatment : Excluded : Lymphocyte replacement . Patients follow exclude : Evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole azoles . Moderate severe liver disease . Satisfactory response amphotericin B receive total amphotericin B dose 15 mg/kg since CSF culture documentation current episode acute cryptococcal meningitis . Life expectancy &lt; 2 week . Prior Medication : Excluded : Coumadintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Prior Treatment : Excluded : Lymphocyte replacement .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1990</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
</DOC>